Intrinsic value of Collegium Pharmaceutical - COLL

Previous Close

$20.15

  Intrinsic Value

$0.87

stock screener

  Rating & Target

str. sell

-96%

Previous close

$20.15

 
Intrinsic value

$0.87

 
Up/down potential

-96%

 
Rating

str. sell

We calculate the intrinsic value of COLL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  45
  69
  104
  150
  212
  291
  391
  513
  661
  834
  1,036
  1,267
  1,527
  1,817
  2,136
  2,485
  2,863
  3,268
  3,702
  4,162
  4,648
  5,160
  5,698
  6,260
  6,848
  7,461
  8,099
  8,763
  9,453
  10,171
Variable operating expenses, $m
  502
  775
  1,160
  1,682
  2,374
  3,263
  4,380
  5,752
  7,401
  9,348
  11,608
  14,192
  17,106
  20,353
  23,931
  27,838
  32,067
  36,611
  41,464
  46,618
  52,066
  57,803
  63,824
  70,126
  76,709
  83,573
  90,722
  98,159
  105,893
  113,931
Fixed operating expenses, $m
  81
  83
  84
  86
  88
  90
  92
  94
  96
  98
  100
  103
  105
  107
  109
  112
  114
  117
  119
  122
  125
  128
  130
  133
  136
  139
  142
  145
  148
  152
Total operating expenses, $m
  583
  858
  1,244
  1,768
  2,462
  3,353
  4,472
  5,846
  7,497
  9,446
  11,708
  14,295
  17,211
  20,460
  24,040
  27,950
  32,181
  36,728
  41,583
  46,740
  52,191
  57,931
  63,954
  70,259
  76,845
  83,712
  90,864
  98,304
  106,041
  114,083
Operating income, $m
  -538
  -789
  -1,140
  -1,618
  -2,250
  -3,062
  -4,081
  -5,332
  -6,836
  -8,612
  -10,672
  -13,028
  -15,684
  -18,643
  -21,904
  -25,465
  -29,318
  -33,460
  -37,882
  -42,579
  -47,543
  -52,770
  -58,257
  -63,999
  -69,997
  -76,252
  -82,765
  -89,542
  -96,588
  -103,912
EBITDA, $m
  -537
  -788
  -1,139
  -1,617
  -2,248
  -3,059
  -4,078
  -5,328
  -6,831
  -8,604
  -10,663
  -13,016
  -15,670
  -18,627
  -21,886
  -25,443
  -29,294
  -33,431
  -37,850
  -42,542
  -47,503
  -52,725
  -58,207
  -63,945
  -69,938
  -76,187
  -82,695
  -89,466
  -96,506
  -103,823
Interest expense (income), $m
  0
  0
  1
  2
  4
  7
  10
  15
  21
  28
  36
  46
  57
  70
  85
  102
  120
  140
  161
  184
  209
  235
  263
  292
  323
  355
  388
  423
  459
  497
  537
Earnings before tax, $m
  -538
  -790
  -1,143
  -1,623
  -2,257
  -3,072
  -4,096
  -5,353
  -6,864
  -8,648
  -10,718
  -13,085
  -15,754
  -18,728
  -22,006
  -25,585
  -29,458
  -33,621
  -38,067
  -42,788
  -47,778
  -53,033
  -58,549
  -64,322
  -70,352
  -76,640
  -83,188
  -90,001
  -97,085
  -104,448
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -538
  -790
  -1,143
  -1,623
  -2,257
  -3,072
  -4,096
  -5,353
  -6,864
  -8,648
  -10,718
  -13,085
  -15,754
  -18,728
  -22,006
  -25,585
  -29,458
  -33,621
  -38,067
  -42,788
  -47,778
  -53,033
  -58,549
  -64,322
  -70,352
  -76,640
  -83,188
  -90,001
  -97,085
  -104,448

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  76
  117
  175
  255
  359
  494
  663
  870
  1,120
  1,414
  1,756
  2,147
  2,588
  3,079
  3,621
  4,212
  4,852
  5,539
  6,274
  7,054
  7,878
  8,746
  9,657
  10,610
  11,606
  12,645
  13,727
  14,852
  16,022
  17,238
Adjusted assets (=assets-cash), $m
  76
  117
  175
  255
  359
  494
  663
  870
  1,120
  1,414
  1,756
  2,147
  2,588
  3,079
  3,621
  4,212
  4,852
  5,539
  6,274
  7,054
  7,878
  8,746
  9,657
  10,610
  11,606
  12,645
  13,727
  14,852
  16,022
  17,238
Revenue / Adjusted assets
  0.592
  0.590
  0.594
  0.588
  0.591
  0.589
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
Average production assets, $m
  4
  6
  9
  13
  18
  25
  34
  45
  57
  73
  90
  110
  133
  158
  186
  216
  249
  284
  322
  362
  404
  449
  496
  545
  596
  649
  705
  762
  822
  885
Working capital, $m
  -6
  -9
  -14
  -20
  -29
  -40
  -53
  -70
  -90
  -113
  -141
  -172
  -208
  -247
  -291
  -338
  -389
  -444
  -503
  -566
  -632
  -702
  -775
  -851
  -931
  -1,015
  -1,101
  -1,192
  -1,286
  -1,383
Total debt, $m
  17
  43
  79
  128
  193
  277
  382
  511
  666
  850
  1,062
  1,306
  1,580
  1,885
  2,222
  2,590
  2,988
  3,415
  3,872
  4,357
  4,870
  5,410
  5,976
  6,570
  7,189
  7,835
  8,508
  9,208
  9,936
  10,692
Total liabilities, $m
  47
  73
  109
  158
  223
  307
  412
  541
  697
  880
  1,092
  1,336
  1,610
  1,915
  2,252
  2,620
  3,018
  3,446
  3,902
  4,387
  4,900
  5,440
  6,007
  6,600
  7,219
  7,865
  8,538
  9,238
  9,966
  10,722
Total equity, $m
  29
  44
  66
  96
  136
  187
  251
  329
  423
  535
  664
  812
  978
  1,164
  1,369
  1,592
  1,834
  2,094
  2,371
  2,666
  2,978
  3,306
  3,650
  4,011
  4,387
  4,780
  5,189
  5,614
  6,056
  6,516
Total liabilities and equity, $m
  76
  117
  175
  254
  359
  494
  663
  870
  1,120
  1,415
  1,756
  2,148
  2,588
  3,079
  3,621
  4,212
  4,852
  5,540
  6,273
  7,053
  7,878
  8,746
  9,657
  10,611
  11,606
  12,645
  13,727
  14,852
  16,022
  17,238
Debt-to-equity ratio
  0.600
  0.970
  1.190
  1.330
  1.420
  1.480
  1.530
  1.550
  1.570
  1.590
  1.600
  1.610
  1.610
  1.620
  1.620
  1.630
  1.630
  1.630
  1.630
  1.630
  1.640
  1.640
  1.640
  1.640
  1.640
  1.640
  1.640
  1.640
  1.640
  1.640
Adjusted equity ratio
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378
  0.378

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -538
  -790
  -1,143
  -1,623
  -2,257
  -3,072
  -4,096
  -5,353
  -6,864
  -8,648
  -10,718
  -13,085
  -15,754
  -18,728
  -22,006
  -25,585
  -29,458
  -33,621
  -38,067
  -42,788
  -47,778
  -53,033
  -58,549
  -64,322
  -70,352
  -76,640
  -83,188
  -90,001
  -97,085
  -104,448
Depreciation, amort., depletion, $m
  0
  1
  1
  1
  2
  3
  3
  4
  6
  7
  9
  11
  13
  16
  19
  22
  25
  28
  32
  36
  40
  45
  50
  54
  60
  65
  70
  76
  82
  88
Funds from operations, $m
  -537
  -789
  -1,142
  -1,621
  -2,255
  -3,070
  -4,093
  -5,348
  -6,858
  -8,640
  -10,709
  -13,074
  -15,741
  -18,712
  -21,988
  -25,563
  -29,433
  -33,593
  -38,034
  -42,751
  -47,738
  -52,988
  -58,499
  -64,267
  -70,293
  -76,575
  -83,118
  -89,925
  -97,003
  -104,360
Change in working capital, $m
  -2
  -3
  -5
  -6
  -8
  -11
  -14
  -17
  -20
  -24
  -27
  -31
  -35
  -39
  -43
  -47
  -51
  -55
  -59
  -63
  -66
  -70
  -73
  -77
  -80
  -83
  -87
  -90
  -94
  -98
Cash from operations, $m
  -535
  -786
  -1,137
  -1,615
  -2,247
  -3,059
  -4,079
  -5,332
  -6,838
  -8,617
  -10,682
  -13,042
  -15,706
  -18,673
  -21,944
  -25,515
  -29,382
  -33,538
  -37,975
  -42,689
  -47,672
  -52,919
  -58,426
  -64,191
  -70,213
  -76,492
  -83,031
  -89,835
  -96,909
  -104,262
Maintenance CAPEX, $m
  0
  0
  -1
  -1
  -1
  -2
  -3
  -3
  -4
  -6
  -7
  -9
  -11
  -13
  -16
  -19
  -22
  -25
  -28
  -32
  -36
  -40
  -45
  -50
  -54
  -60
  -65
  -70
  -76
  -82
New CAPEX, $m
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -11
  -13
  -15
  -18
  -20
  -23
  -25
  -28
  -30
  -33
  -35
  -38
  -40
  -42
  -45
  -47
  -49
  -51
  -53
  -56
  -58
  -60
  -62
Cash from investing activities, $m
  -1
  -2
  -4
  -5
  -6
  -9
  -12
  -14
  -17
  -21
  -25
  -29
  -34
  -38
  -44
  -49
  -55
  -60
  -66
  -72
  -78
  -85
  -92
  -99
  -105
  -113
  -121
  -128
  -136
  -144
Free cash flow, $m
  -537
  -788
  -1,141
  -1,620
  -2,253
  -3,068
  -4,090
  -5,346
  -6,855
  -8,638
  -10,706
  -13,072
  -15,739
  -18,712
  -21,988
  -25,564
  -29,437
  -33,598
  -38,042
  -42,761
  -47,750
  -53,004
  -58,518
  -64,289
  -70,318
  -76,605
  -83,152
  -89,963
  -97,046
  -104,407
Issuance/(repayment) of debt, $m
  17
  26
  36
  49
  65
  84
  105
  129
  155
  183
  213
  243
  274
  306
  337
  368
  398
  428
  457
  485
  513
  540
  567
  593
  620
  646
  673
  700
  728
  756
Issuance/(repurchase) of shares, $m
  548
  805
  1,165
  1,653
  2,296
  3,123
  4,160
  5,431
  6,958
  8,759
  10,847
  13,233
  15,921
  18,914
  22,211
  25,808
  29,700
  33,881
  38,344
  43,082
  48,090
  53,361
  58,893
  64,682
  70,729
  77,033
  83,597
  90,427
  97,528
  104,908
Cash from financing (excl. dividends), $m  
  565
  831
  1,201
  1,702
  2,361
  3,207
  4,265
  5,560
  7,113
  8,942
  11,060
  13,476
  16,195
  19,220
  22,548
  26,176
  30,098
  34,309
  38,801
  43,567
  48,603
  53,901
  59,460
  65,275
  71,349
  77,679
  84,270
  91,127
  98,256
  105,664
Total cash flow (excl. dividends), $m
  29
  43
  60
  82
  108
  139
  175
  215
  258
  305
  354
  404
  456
  508
  560
  611
  662
  711
  759
  806
  852
  898
  942
  986
  1,030
  1,074
  1,118
  1,164
  1,210
  1,258
Retained Cash Flow (-), $m
  -548
  -805
  -1,165
  -1,653
  -2,296
  -3,123
  -4,160
  -5,431
  -6,958
  -8,759
  -10,847
  -13,233
  -15,921
  -18,914
  -22,211
  -25,808
  -29,700
  -33,881
  -38,344
  -43,082
  -48,090
  -53,361
  -58,893
  -64,682
  -70,729
  -77,033
  -83,597
  -90,427
  -97,528
  -104,908
Prev. year cash balance distribution, $m
  86
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  7
  11
  17
  26
  38
  53
  73
  98
  128
  165
  209
  259
  317
  382
  454
  534
  621
  716
  817
  925
  1,040
  1,162
  1,290
  1,424
  1,565
  1,712
  1,865
  2,025
  2,191
  2,363
Cash available for distribution, $m
  -434
  -762
  -1,105
  -1,571
  -2,188
  -2,984
  -3,985
  -5,217
  -6,700
  -8,454
  -10,494
  -12,828
  -15,465
  -18,406
  -21,651
  -25,197
  -29,039
  -33,170
  -37,585
  -42,276
  -47,238
  -52,464
  -57,951
  -63,696
  -69,699
  -75,959
  -82,479
  -89,263
  -96,318
  -103,650
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -416
  -698
  -961
  -1,293
  -1,696
  -2,166
  -2,692
  -3,261
  -3,849
  -4,432
  -4,983
  -5,474
  -5,880
  -6,179
  -6,356
  -6,403
  -6,318
  -6,109
  -5,787
  -5,372
  -4,886
  -4,353
  -3,798
  -3,244
  -2,711
  -2,216
  -1,770
  -1,381
  -1,051
  -780
Current shareholders' claim on cash, %
  16.2
  2.8
  0.5
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

FINANCIAL RATIOS  of  Collegium Pharmaceutical (COLL)

Valuation Ratios
P/E Ratio -6.3
Price to Sales 295.8
Price to Book 4.4
Price to Tangible Book
Price to Cash Flow -7.9
Price to Free Cash Flow -7.6
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 51
Current Ratio 0
LT Debt to Equity 0.7%
Total Debt to Equity 3%
Interest Coverage 0
Management Effectiveness
Return On Assets -72.3%
Ret/ On Assets - 3 Yr. Avg. -106.6%
Return On Total Capital -81.4%
Ret/ On T. Cap. - 3 Yr. Avg. -173.5%
Return On Equity -85.5%
Return On Equity - 3 Yr. Avg. 176.1%
Asset Turnover 0
Profitability Ratios
Gross Margin 100%
Gross Margin - 3 Yr. Avg. 33.3%
EBITDA Margin -4650%
EBITDA Margin - 3 Yr. Avg. -1550%
Operating Margin -4700%
Oper. Margin - 3 Yr. Avg. -1566.7%
Pre-Tax Margin -4700%
Pre-Tax Margin - 3 Yr. Avg. -1566.7%
Net Profit Margin -4700%
Net Profit Margin - 3 Yr. Avg. -1566.7%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

COLL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the COLL stock intrinsic value calculation we used $28 million for the last fiscal year's total revenue generated by Collegium Pharmaceutical. The default revenue input number comes from 2017 income statement of Collegium Pharmaceutical. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our COLL stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for COLL is calculated based on our internal credit rating of Collegium Pharmaceutical, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Collegium Pharmaceutical.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of COLL stock the variable cost ratio is equal to 1120.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $79 million in the base year in the intrinsic value calculation for COLL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Collegium Pharmaceutical.

Corporate tax rate of 27% is the nominal tax rate for Collegium Pharmaceutical. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the COLL stock is equal to 25%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for COLL are equal to 8.7%.

Life of production assets of 10 years is the average useful life of capital assets used in Collegium Pharmaceutical operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for COLL is equal to -13.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $104 million for Collegium Pharmaceutical - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 30 million for Collegium Pharmaceutical is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Collegium Pharmaceutical at the current share price and the inputted number of shares is $0.6 billion.

RELATED COMPANIES Price Int.Val. Rating
NKTR Nektar Therape 48.73 104.62  hold
PFE Pfizer 37.33 24.58  sell
JNJ Johnson&Johnso 125.85 126.96  hold

COMPANY NEWS

▶ Collegium Announces Promotion of Scott Dreyer to CCO   [Jul-10-18 07:30AM  GlobeNewswire]
▶ Collegium Announces CEO Succession   [Jun-04-18 04:01PM  GlobeNewswire]
▶ Collegium to Present at Upcoming Investor Conferences   [May-30-18 04:01PM  GlobeNewswire]
▶ Why Depomed Inc.'s Shares Soared 23.2% Higher   [May-10-18 05:40PM  Motley Fool]
▶ Collegium Pharmaceutical: 1Q Earnings Snapshot   [May-09-18 04:14PM  Associated Press]
▶ Collegium to Present at Upcoming Investor Conferences   [Mar-16-18 08:06AM  GlobeNewswire]
▶ Top Growth Stocks To Buy Now   [Mar-10-18 11:03AM  Simply Wall St.]
▶ Trump Tones Down Tariff Talk   [Mar-09-18 09:15AM  Zacks]
▶ This Biotech Flirts With Breakout Amid Battle With Opioid Makers   [Mar-08-18 04:48PM  Investor's Business Daily]
▶ Collegium Pharmaceutical posts 4Q loss   [Mar-07-18 04:09PM  Associated Press]
▶ 3 Top-Ranked Drug Stocks That Are Broker Favorites   [Jan-18-18 09:25AM  InvestorPlace]
▶ Harry Boxers three health-care stocks to watch today   [Jan-10-18 11:39AM  MarketWatch]
▶ Depomed Executes an Exit Strategy for Its Opioid Drug   [Dec-06-17 12:05PM  Motley Fool]
▶ How Two Drugmakers Rocketed On A Deal That Sees One Exit Opioid Sales   [Dec-05-17 02:29PM  Investor's Business Daily]
▶ Harry Boxer on four stocks rallying today   [Nov-16-17 02:03PM  MarketWatch]
▶ Collegium Pharmaceutical posts 3Q loss   [Nov-08-17 05:25PM  Associated Press]
▶ Collegium Receives FDA Approval for sNDA for Xtampza® ER   [Nov-07-17 08:30AM  GlobeNewswire]
▶ Collegium to Present at Upcoming Investor Conferences   [Sep-06-17 07:00AM  GlobeNewswire]
▶ Collegium Pharmaceutical posts 2Q loss   [Aug-09-17 09:16PM  Associated Press]
▶ How Endo's Opioid Pitfall Could Be A Boon For These Drugmakers   [Jun-09-17 04:07PM  Investor's Business Daily]
▶ Collegium to Present at Upcoming Investor Conferences   [May-23-17 07:52AM  GlobeNewswire]
▶ Collegium Pharmaceutical posts 1Q loss   [May-10-17 04:24PM  Associated Press]
▶ BioDelivery Sciences Secures Two Patents   [Mar-31-17 10:56AM  Investopedia]
▶ BioDelivery Sciences Secures Two Patents   [10:56AM  at Investopedia]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.